Skip to content
DataLookout
Menu

NCT07487727

A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved 3 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 6 words Show 4 more changesShow less
    • Primary completion pushed from Dec 1, 2026 to Mar 1, 2027
    • Study completion pushed from Jul 1, 2027 to Aug 1, 2027
    • Secondary endpoints: details revised at 6 of 15 entries
    • Site details revised
  2. Notable Eligibility criteria expanded, about 15 words
    • Primary endpoint revised
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Evaluate the efficacy of AND017 compared with the active control in maintaining Hemoglobin (Hb) levels in patients with anemia due to CKD
Timeframe: From Week 23 to Week 27

Secondary (15)

The percentage of responders
Percentage of participants that maintained Hb level over target lower limit
Maintenance of Hb within 10.0-12.0 g/dL after initial achievement ≥10.0 g/dL during the entire study treatment period
Incidence of extreme Hb levels of ≥13.0 g/dL or <7.5 g/dL during the entire study treatment period
Incidence of excessive erythropoiesis
Show 10 moreShow less
The cumulative incidence of Hb non-response
Mean Hb change from baseline averaged over Weeks 5-27
Mean Hb change from baseline averaged over Weeks 23-27
Mean Hb change from baseline averaged over Weeks 13-17
Mean Hb change from baseline averaged over Weeks 27-53
Mean Hb change from baseline averaged over Weeks 49-53
During the entire treatment period, mean Hb at each visit
The use of intravenous iron during the entire study treatment period
The mean weekly dose of intravenous iron during the entire treatment period
The time to first initiation of intravenous iron during the entire treatment period

Arms and interventions

AND017Experimental
Erythropoiesis Stimulating Agents (ESA)Active comparator

Drugs: AND017, ESA

Sites

1 site in 1 country

  • Peking University People's HospitalBeijing, Beijing Municipality, China